Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Clinical evidence

BCA101X1101

104 evidence topics · 11 sources

Objective
Location and study date
Registry study dates
Study characteristicQuoted record
Study start (actual)“2020-06-01”
Primary completion (estimated)“2027-10-31”
Study completion (estimated)“2028-03-30”
Study design
Registry design: nonrandomized, open-label, parallel assignment
Study characteristicQuoted record
Protocol number“BCA101X1101”
Merck study identifier“KEYNOTE-E28”
Allocation“Non-Randomized”
Interventional model“Parallel Assignment”
Masking“None (Open Label)”
Eligibility criteria
Registry criteria for the first-line HNSCC combination cohort (expansion cohort 2)

“Expansion Cohort 2: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) equal to or greater than 1, as determined by an CLIA-approved laboratory test.” (opens the source at this quote in a new tab)

“Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx.” (opens the source at this quote in a new tab)

“Participants may not have a primary tumor site of nasopharynx (any histology).” (opens the source at this quote in a new tab)

“Patients must have no prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally advanced disease) or prior history of immune checkpoint inhibitors with the exception of neoadjuvant therapy (>6 months prior to study drug initiation).” (opens the source at this quote in a new tab)

“No prior history of anti-EGFR antibodies (with the exception of radiosensitizing agents and multimodal treatment for locally advanced disease).” (opens the source at this quote in a new tab)

“Patients must provide tissue for PD-L1 biomarker analysis from a core or excisional biopsy (fine needle aspirate is not sufficient): A newly obtained biopsy (within 90 days prior to start of study treatment) is preferred but an archival sample is acceptable.” (opens the source at this quote in a new tab)

“Patients must have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer” (opens the source at this quote in a new tab)

Treatment
Dose escalation: dose range, starting doses, and infusion

“At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The starting dosage of ficerafusp alfa in monotherapy for patients enrolled in the study was set at 64 mg i.v. administered continuously once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The selected starting dosage followed the International Council for Harmonization S9 guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Ficerafusp alfa was administered as an infusion over 120 minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The starting dosage of ficerafusp alfa in combination with pembrolizumab was 240 mg i.v. once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab 200 mg i.v. was administered after ficerafusp alfa as a 30-minute infusion every 3 weeks (cycle length, 21 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“64, 240, 500, 750, 800, 1,000, 1,250, and 1,500 mg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

First-line 1500 mg weekly regimen and dose modification rules

“Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.” (opens the source at this quote in a new tab)

“Treatment beyond progression was permitted at the discretion of the treating investigator if the patient was deriving clinical benefit.” (opens the source at this quote in a new tab)

“Pembrolizumab was interrupted or discontinued (dose reduction not permitted) for grade ≥3 immune-related adverse events (AEs) per investigator assessment.” (opens the source at this quote in a new tab)

“The infusion rate of ficerafusp alfa was reduced by 50% for grade 1/2 or nonserious infusion-related reactions (IRRs); ficerafusp alfa was permanently discontinued for grade ≥3 or serious IRRs.” (opens the source at this quote in a new tab)

“Grade ≥3 AEs resulted in interruption, dose modification (ficerafusp alfa only), or permanent discontinuation according to study drug attribution.” (opens the source at this quote in a new tab)

“Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.” (opens the source at this quote in a new tab)

“Patients who discontinued one study drug for any reason other than disease progression could continue the other per investigator discretion.” (opens the source at this quote in a new tab)

Study outcomes
Rationale for using dose-limiting toxicities and adverse events as the primary endpoints
First-line 1500 mg weekly cohort: safety as the primary endpoint and efficacy endpoint definitions
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment across all cohorts
Study characteristicQuoted record
Enrollment (estimated)“473”
Description of analysis sets
Dose escalation analysis sets

“Descriptive statistics were used to summarize all patient characteristics, treatment administration and compliance, efficacy endpoints, and safety parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The safety set included all patients who received at least one dose of study treatment, ficerafusp alfa or pembrolizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The dose-determining set included all patients in the safety set who enrolled during dose escalation and either experienced a DLT at any time during the DLT evaluation period (first 21 days) or had all required safety assessments without experiencing a DLT within the DLT evaluation period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The efficacy-evaluable set included all patients who received at least one dose of study treatment and had at least one post-baseline tumor assessment as defined in the protocol at or beyond the first post-baseline visit for tumor assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“If a patient had progressive disease before the first post–baseline assessment visit, they were also included in the efficacy-evaluable set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The PK analysis set consisted of all patients who had at least one blood sample providing evaluable PK data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The duration of response analysis was performed using Kaplan–Meier methods.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Results
Participant disposition
First-line 1500 mg weekly cohort: reasons for treatment or study discontinuation
Status or reasonSafety set (N = 42), No. (%)Efficacy-evaluable set (n = 39), No. (%)
Treatment ongoing“3 (7)”“3 (7)”
Treatment discontinuation“39 (93)”“36 (92)”
Treatment discontinuation: progression of disease“21 (50)”“20 (51)”
Treatment discontinuation: adverse event“10 (24)”“8 (21)”
Treatment discontinuation: patient withdrawal“5 (12)”“5 (13)”
Treatment discontinuation: investigator discretion“3 (7)”“3 (8)”
Study follow-up ongoing“12 (29)”“12 (31)”
Study follow-up discontinued“30 (71)”“27 (69)”
Study follow-up discontinued: death“29 (69)”“26 (67)”
Study follow-up discontinued: patient withdrawal“1 (2)”“1 (3)”
Study follow-up discontinued: lost to follow-up“0”“0”
Baseline characteristics
First-line HPV-negative dose cohorts at the March 2026 data cut
Characteristic750 mg QW (N=31)1500 mg QW (N=30)2000 mg Q2W (N=30)
Age, median (min-max)“64 (28-78)”“63 (31-84)”“63 (32-94)”
Male, n (%)“20 (65)”“19 (63)”“20 (67)”
Female, n (%)“11 (35)”“11 (37)”“10 (33)”
Oral cavity, n (%)“19 (61)”“14 (47)”“19 (63)”
Oropharynx (HPV negative), n (%)“4 (13)”“8 (27)”“6 (20)”
Hypopharynx, n (%)“5 (16)”“4 (13)”“2 (7)”
Larynx, n (%)“3 (10)”“4 (13)”“3 (10)”
CPS 1-19, n (%)“12 (39)”“15 (50)”“15 (50)”
CPS ≥20, n (%)“19 (61)”“15 (50)”“15 (50)”
Locoregional only, (%)“16 (52)”“9 (30)”“19 (63)”
Distant metastatic only, (%)“5 (16)”“7 (23)”“5 (17)”
Locoregional and distant metastatic, (%)“10 (32)”“14 (47)”“6 (20)”
Target lesion diameter (mm) at baseline, median (min-max)“41 (11-131)”“49 (10-133)”“33 (10-187)”
Sum of target lesion diameters >50 mm, n (%)“10 (32)”“14 (47)”“11 (37)”
Sum of target lesion diameters >70 mm, n (%)“4 (13)”“8 (27)”“7 (23)”
ECOG PS 0, n (%)“11 (35)”“11 (37)”“10 (33)”
ECOG PS 1, n (%)“20 (65)”“19 (63)”“20 (67)”
First-line 1500 mg weekly cohort by HPV status
CharacteristicParticipants (N = 42)HPV-positive (n = 12)HPV-negative (n = 30)
Age, years, median (range)“63 (31-84)”“65 (48-77)”“63 (31-84)”
Male, No. (%)“30 (71)”“11 (92)”“19 (63)”
Female, No. (%)“12 (29)”“1 (8)”“11 (37)”
White/Caucasian, No. (%)“34 (81)”“10 (83)”“24 (80)”
Black or African American, No. (%)“3 (7)”“1 (8)”“2 (7)”
Asian, No. (%)“1 (2)”“0”“1 (3)”
Multiple races, No. (%)“1 (2)”“0”“1 (3)”
Race not reported, No. (%)“3 (7)”“1 (8)”“2 (7)”
ECOG performance status 0, No. (%)“15 (36)”“4 (33)”“11 (37)”
ECOG performance status 1, No. (%)“27 (64)”“8 (67)”“19 (63)”
Oropharynx, No. (%)“20 (48)”“12 (100)”“8 (27)”
Oral cavity, No. (%)“14 (33)”“0”“14 (47)”
Hypopharynx, No. (%)“4 (10)”“0”“4 (13)”
Larynx, No. (%)“4 (10)”“0”“4 (13)”
CPS at screening 1-19, No. (%)“22 (52)”“7 (58)”“15 (50)”
CPS at screening ≥20, No. (%)“20 (48)”“5 (42)”“15 (50)”
Locoregional only, No. (%)“11 (26)”“2 (17)”“9 (30)”
Locoregional and distant metastatic, No. (%)“17 (40)”“3 (25)”“14 (47)”
Distant metastatic only, No. (%)“14 (33)”“7 (58)”“7 (23)”
Sum of target lesion diameters ≤50 mm, No. (%)“24 (57)”“8 (67)”“16 (53)”
Sum of target lesion diameters >50 mm, No. (%)“18 (43)”“4 (33)”“14 (47)”
Sum of target lesion diameters >70 mm, No. (%)“11 (26)”“3 (25)”“8 (27)”
Prior radiotherapy in the LA HNSCC setting, No. (%)“33 (79)”“9 (75)”“24 (80)”
Prior platinum-based chemotherapy, No. (%)“27 (64)”“12 (100)”“15 (50)”
Dose escalation participants
CharacteristicFicerafusp alfa monotherapy (n = 46)Ficerafusp alfa + pembrolizumab (n = 15)Total population (N = 61)
Age (years), median (range)“61 (43–82)”View highlighted excerpt for this quote“66 (42–81)”View highlighted excerpt for this quote“62 (42–82)”View highlighted excerpt for this quote
Female, n (%)“23 (50)”View highlighted excerpt for this quote“5 (33)”View highlighted excerpt for this quote“28 (46)”View highlighted excerpt for this quote
Male, n (%)“23 (50)”View highlighted excerpt for this quote“10 (67)”View highlighted excerpt for this quote“33 (54)”View highlighted excerpt for this quote
ECOG performance status 0, n (%)“13 (28)”View highlighted excerpt for this quote“4 (27)”View highlighted excerpt for this quote“17 (28)”View highlighted excerpt for this quote
ECOG performance status 1, n (%)“33 (72)”View highlighted excerpt for this quote“10 (67)”View highlighted excerpt for this quote“43 (70)”View highlighted excerpt for this quote
HNSCC, n (%)“7 (15)”View highlighted excerpt for this quote“7 (47)”View highlighted excerpt for this quote“14 (23)”View highlighted excerpt for this quote
SCAC, n (%)“1 (2)”View highlighted excerpt for this quote“8 (53)”View highlighted excerpt for this quote“9 (15)”View highlighted excerpt for this quote
Number of prior antineoplastic therapies, median (range)“4 (1–7)”View highlighted excerpt for this quote“2 (1–8)”View highlighted excerpt for this quote“3 (1–8)”View highlighted excerpt for this quote
Prior anti-EGFR treatment, n (%)“13 (28)”View highlighted excerpt for this quote“5 (33)”View highlighted excerpt for this quote“18 (30)”View highlighted excerpt for this quote
Prior anti–PD-(L)1 treatment, n (%)“21 (46)”View highlighted excerpt for this quote“9 (60)”View highlighted excerpt for this quote“30 (49)”View highlighted excerpt for this quote
Efficacy results
Data snapshot of 9 July 2025, 750 mg weekly cohort: response by combined positive score and tumor burden
SubgroupObjective response rate
Combined positive score 1-19“73% (8/11)”
Combined positive score ≥20“47% (9/19)”
Sum of target lesion diameters ≤50 mm“55% (11/20)”
Sum of target lesion diameters >50 mm“60% (6/10)”
Sum of target lesion diameters >70 mm“50% (2/4)”
Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: response
OutcomeEfficacy-evaluable set (N=27)
Confirmed objective response rate“48% (13/27)”
Disease control rate“85% (23/27)”
Deep response among responders“77% (10/13)”
Complete response rate“26% (7/27)”
Median time to response“1.6 months”
Objective response rate, combined positive score 1-19“57% (8/14)”
Objective response rate, combined positive score ≥20“39% (5/13)”
Data snapshot of 16 December 2025, 750 mg and 1500 mg weekly cohorts: efficacy by cohort
OutcomeFicerafusp alfa 750 mg plus pembrolizumab (N=30)Ficerafusp alfa 1500 mg plus pembrolizumab (N=28)
Confirmed objective response rate/complete response rate, n (%)“17 (57)/4 (13)”“15 (54)/6 (21)”
Responders with ≥80% shrinkage, n (%)“8/17 (47)”“12/15 (80)”
Median duration of response, months“NR”“21.7”
Proportion of responses >12 months, n (%)“9/17 (53)”“9/15 (60)”
Median progression-free survival, months“6.9”“9.9”
Data snapshot of 31 March 2026, three cohorts: response by cohort
OutcomeFicerafusp alfa 750 mg weeklyFicerafusp alfa 1500 mg weeklyFicerafusp alfa 2000 mg every 2 weeks
Confirmed objective response rate (95% CI)“57% (37%-74%)”“54% (34%-72%)”“48% (29%-68%)”
Deep response among responders“47% (8/17)”“80% (12/15)”“77% (10/13)”
Data snapshot of 31 March 2026, three cohorts: company summary of efficacy by cohort
OutcomeFicerafusp alfa 750 mg weekly (n=30)Ficerafusp alfa 1500 mg weekly (n=28)Ficerafusp alfa 2000 mg every 2 weeks (n=27)
Confirmed overall response rate“57%”“54%”“48%”
Complete response rate“13%”“25%”“30%”
Deep (≥80%) responses“47%”“80%”“77%”
Median time to response“1.6 months”“1.4 months”“1.6 months”
Median duration of response“NR (>16.6 months)”“21.7 months”“NR (>12.8 months)”
Median progression-free survival“6.9 months”“9.9 months”“12.7 months”
Median overall survival“NM (>19.4 months)”“21.3 months”“NM (>12.7 months; >23.6 months in patients with > 2-year follow-up)”
Data snapshot of 31 March 2026, three cohorts: progression-free and overall survival with confidence intervals
OutcomeFicerafusp alfa 750 mg weeklyFicerafusp alfa 1500 mg weeklyFicerafusp alfa 2000 mg every 2 weeks
Median progression-free survival (95% CI), months“6.9 (4.6-NE)”“9.9 (4.4-22.7)”“12.7 (4.9-NE)”
Median overall survival (95% CI), months“Not mature”“21.3 (9.9-33.6)”“Not mature”
Data snapshot of 31 March 2026, three cohorts: confirmed response by combined positive score, tumor burden, and extent of disease
Subgroup, % (n/N)Ficerafusp alfa 750 mg weekly (n=30)Ficerafusp alfa 1500 mg weekly (n=28)Ficerafusp alfa 2000 mg every 2 weeks (n=27)
Combined positive score 1-19“73 (8/11)”“54 (7/13)”“57 (8/14)”
Combined positive score ≥20“47 (9/19)”“53 (8/15)”“38 (5/13)”
Sum of target lesion diameters ≤50 mm“55 (11/20)”“53 (8/15)”“53 (9/17)”
Sum of target lesion diameters >50 mm“60 (6/10)”“54 (7/13)”“40 (4/10)”
Sum of target lesion diameters >70 mm“50 (2/4)”“43 (3/7)”“33 (2/6)”
Locoregional disease only“38 (6/16)”“62 (5/8)”“50 (7/14)”
Distant metastatic disease only“100 (5/5)”“29 (2/7)”“40 (2/5)”
Locoregional and distant metastatic disease“67 (6/9)”“62 (8/13)”“50 (4/8)”
Data snapshot of 31 March 2026, three cohorts pooled: median duration of response, progression-free survival, and overall survival by best response
Best response groupMedian duration of response (95% CI), monthsMedian progression-free survival (95% CI), monthsMedian overall survival (95% CI), months
Deep response (n=30)“31.6 (21.6-NE)”“36.9 (22.7-NE)”“Not reached (26.3-NE)”
Partial response <80% (n=15)“8.2 (4.0-NE)”“10.9 (5.6-NE)”“33.6 (10.9-NE)”
Data snapshot of 31 March 2026, three cohorts pooled: progression-free and overall survival with stable or progressive disease
Best response groupMedian progression-free survival (95% CI), monthsMedian overall survival (95% CI), months
Stable disease (n=26)“5.8 (3.6-6.8)”“11.3 (9.0-20.6)”
Progressive disease (n=14)“1.4 (1.3-1.5)”“7.3 (2.4-17.1)”
Health-related quality of life and patient-reported outcomes
Patient-reported outcomes not assessed in the 1500 mg weekly expansion cohort
Safety results
Dose escalation in advanced solid tumors: combination arm

“The MTD was not reached in either cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“TRAEs were reported for 87% (40 of 46) and 87% (13 of 15) of patients treated with ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For ficerafusp alfa in combination with pembrolizumab, the most common TRAEs were acneiform dermatitis (73%; 11 of 15), fatigue (53%; eight of 15), epistaxis (40%; six of 15), pruritus (40%; six of 15), and maculopapular rash (40%; six of 15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For ficerafusp alfa in combination with pembrolizumab, serious TRAEs included grade 3 anemia (n = 1), grade 3 stomatitis with grade 3 atrial fibrillation (n = 1), and grade 3 stomatitis with grade 3 pneumonitis (n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two patients treated with ficerafusp alfa in combination with pembrolizumab discontinued both drugs because of grade 3 reactive lichen planus and grade 3 atrial fibrillation, respectively. No grade 4 TRAEs or treatment-related deaths were observed in either cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Data snapshot of 20 March 2025, 1500 mg weekly cohort: summary of treatment-related adverse events
Safety outcomeParticipants (N = 42), No. (%)
Grade 3 or 4 treatment-related adverse event“20 (48)”
Treatment-related adverse event leading to ficerafusp alfa discontinuation“5 (12)”
Treatment-related adverse event leading to death“0”
Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-related adverse events by grade
Treatment-related adverse eventAny gradeGrade 1/2Grade 3Grade 4
Any treatment-related adverse event“40 (95)”“20 (48)”“19 (45)”“1 (2)”
Dermatitis acneiform“32 (76)”“27 (64)”“5 (12)”“0”
Fatigue“19 (45)”“18 (43)”“1 (2)”“0”
Pruritus“18 (43)”“17 (40)”“1 (2)”“0”
Anemia“15 (36)”“9 (21)”“6 (14)”“0”
Stomatitis“11 (26)”“9 (21)”“2 (5)”“0”
Infusion-related reaction“8 (19)”“7 (17)”“1 (2)”“0”
Epistaxis“6 (14)”“6 (14)”“0”“0”
Gingival bleeding“6 (14)”“6 (14)”“0”“0”
Colitis“5 (12)”“2 (5)”“3 (7)”“0”
Tracheal hemorrhage“2 (5)”“1 (2)”“1 (2)”“0”
Pericarditis“1 (2)”“0”“0”“1 (2)”
Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-emergent adverse events and deaths
Safety outcomeParticipants (N = 42), n (%)
Grade ≥3 treatment-emergent adverse event“33 (79)”
Treatment-emergent adverse event leading to ficerafusp alfa discontinuation“9 (21)”
Treatment-emergent adverse event leading to death“3 (7)”
Data snapshot of 9 July 2025, 750 mg weekly cohort: treatment-related adverse events
Preferred term, n (%)Any grade (N=31)Grade 3 (N=31)
Any treatment-related adverse event“31 (100)”“13 (42)”
Dermatitis acneiform“26 (84)”“1 (3)”
Pruritus“12 (39)”“1 (3)”
Stomatitis“10 (32)”“3 (10)”
Epistaxis“10 (32)”“1 (3)”
Anemia“8 (26)”“3 (10)”
Hypokalemia“7 (23)”“2 (6)”
Data snapshot of 9 July 2025, 750 mg weekly cohort: discontinuations and deaths
Safety outcomeSafety set (N=31)
Treatment-related adverse event leading to ficerafusp alfa discontinuation“2 (6%)”
Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: treatment-emergent adverse events related to ficerafusp alfa
EventAny grade (N=30)Grade 3 (N=30)
Any related treatment-emergent adverse event“29 (97%)”“16 (53%)”
Dermatitis acneiform“24 (80%)”“3 (10%)”
Anemia“14 (47%)”“8 (27%)”
Stomatitis“11 (37%)”“3 (10%)”
Pruritus“11 (37%)”“1 (3%)”
Nausea“9 (30%)”“1 (3%)”
Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: discontinuations, grade 4 and 5 events, and deaths
Safety outcomeSafety set (N=30)
Treatment-related adverse event leading to ficerafusp alfa discontinuation“3 (10%)”
Data snapshot of 31 March 2026, three cohorts: treatment-related adverse events by grade and cohort
Preferred term, n (%)750 mg weekly (N=31), any grade750 mg weekly, grade 31500 mg weekly (N=30), any grade1500 mg weekly, grade 32000 mg every 2 weeks (N=30), any grade2000 mg every 2 weeks, grade 3
Any treatment-related adverse event“31 (100)”“11 (35)”“28 (93)”“15 (50)”“29 (97)”“16 (53)”
Dermatitis acneiform“27 (87)”“1 (3)”“23 (77)”“4 (13)”“24 (80)”“3 (10)”
Pruritus“13 (42)”“1 (3)”“16 (53)”“1 (3)”“11 (37)”“1 (3)”
Anemia“8 (26)”“3 (10)”“13 (43)”“7 (23)”“15 (50)”“8 (27)”
Fatigue“13 (42)”“0 (0)”“11 (37)”“1 (3)”“12 (40)”“1 (3)”
Stomatitis“13 (42)”“4 (13)”“8 (27)”“0”“11 (37)”“3 (10)”
Epistaxis“11 (35)”“1 (3)”“5 (17)”“0”“12 (40)”“0”
Mouth bleeding“8 (26)”“1 (3)”“0”“0”“4 (13)”“0”
Infusion-related reaction“6 (19)”“1 (3)”“4 (13)”“1 (3)”“7 (23)”“0”
Study limitations
Summary

BCA101X1101 is an open-label, nonrandomized, single-arm phase 1/1b trial with investigator-assessed response; the authors state that the single-arm design makes it “difficult to isolate the contribution of individual treatment components”, and comparisons with KEYNOTE-048 are cross-trial. The 1500 mg weekly cohort enrolled participants in the United States and Canada only, did not assess patient-reported outcomes, and did not routinely collect subsequent therapy. The three first-line dose cohorts were analyzed as separate HPV-negative expansion cohorts of 30, 28, and 27 evaluable participants under a Simon two-stage design, with PD-L1 CPS assessed locally by 22C3 “or other validated assay” and HPV-positive participants of the 1500 mg cohort excluded from the integrated analysis. Duration of response and OS are immature in the 750 mg weekly and 2000 mg every 2 weeks cohorts; in the 2000 mg cohort, 12 of 27 evaluable participants had a median follow-up of 11.7 months. The depth-of-response analysis was post hoc, with small subgroups and a threshold that is not validated. The dose-escalation results come from 15 combination-arm participants with heterogeneous tumors and prior therapy.